P
COGT icon

&Partners’s Cogent Biosciences COGT Stock Holding History

&Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Buy
+6,617
New +$232K ﹤0.01% 2231

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

&Partners's COGT Position: Q2 2026 in Review

&Partners opened a new position in Cogent Biosciences (COGT) in Q2 2026: 6,617 shares worth $255K. The stake represents ﹤0.01% of the portfolio and ranks #2231 among its holdings.

323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • &Partners held 6,617 shares of Cogent Biosciences worth $255K as of Q2 2026.
  • Cogent Biosciences was a new &Partners position in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2231 holding.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.